Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
John Boyce
AddedMar 31, 2024
UpdatedMay 31, 2026
John Boyce

John Boyce

Founder, TigerGene

CrunchbaseLinkedIn

John Boyce's Career

TigerGene
TigerGene

Boston, MA, US

Founder
NanoMosaic
NanoMosaic

Woburn, ND, US

Board Member· Board
BrickBio
BrickBio

Boston, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

John Boyce's Career

TigerGene
TigerGene
30Boston, MA, US
Founder

Similar to TigerGene

BiotechonomyBiotechonomyNewton, MA, USBiotechonomyNewton, MA, US

Biotechonomy: A venture capital firm specializing in equity financing and management aid for innovative life science startups.

6
BridGene BiosciencesBridGene BiosciencesSunnyvale, CA, USBiotech, Drug Discoveryest. 2018BridGene BiosciencesSunnyvale, CA, US · est. 2018

BridGene Biosciences: Innovating small molecule biotech for new disease treatment paths.

Series B · $50.5M23
Tech Innovation GroupTech Innovation GroupMedellín, Antioquia Department, COLife SciencesTech Innovation GroupMedellín, Antioquia Department, CO

TIG: A global investor and builder of health and life sciences startups, transforming patents into solutions.

30
NanoMosaic
NanoMosaic
Series A$40.8M302018Woburn, ND, US
Board Member· Board

Leadership at NanoMosaic

Qimin QuanQimin QuanCo-Founder
Audrey WarnerAudrey WarnerCo-Founder

Similar to NanoMosaic

NanoDetection TechnologyNanoDetection TechnologyFranklin Furnace, OH, USBiomarker Detection, Chipsest. 2002NanoDetection TechnologyFranklin Furnace, OH, US · est. 2002

NanoDetection Technology creates advanced chips for swift, multi-biomarker detection.

Pre-Seed · $5.3M5
NanopathNanopathCambridge, MA, USDiagnostics, Womens Healthest. 2019NanopathCambridge, MA, US · est. 2019

Nanopath: A molecular diagnostics firm revolutionizing testing for women's health in a single visit.

Series A · $10.3M30
Nanoscope TechnologiesNanoscope TechnologiesBedford, TX, USDiagnostics, Therapeuticsest. 2009Nanoscope TechnologiesBedford, TX, US · est. 2009

Nanoscope Technologies: Innovating scientific and biomedical solutions since 2009.

Series A · $4M18
Nano Mobile HealthcareNano Mobile HealthcareNew York City, NY, USMedical Devicesest. 2015Nano Mobile HealthcareNew York City, NY, US · est. 2015

Nano Mobile Healthcare: Innovating mobile health tech with breath screening devices for early disease detection.

Public1
BrickBio
BrickBio
Seed$5M92019Boston, MA, US
Board Member· Board

Leadership at BrickBio

Abhishek ChatterjeeAbhishek ChatterjeeCo-Founder

John Boyce's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakBo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGBoard Member · DiDi

People Similar to John Boyce

Bryce KnightBryce KnightCo-Founder · Revenue.comKenneth KelleyKenneth KelleyBoard Member · SeromYx SystemsMichael GeranenMichael GeranenCo-Founder & CEO · Captura BiopharmaCory BerklandCory BerklandBoard Member · Orion BioScienceDon DavidsonDon DavidsonCo-Founder · Creative BioTherapeuticsBrian P McVeighBrian P McVeighBoard Member · Genisphere